BRAF and Lynch syndrome: Foundation Medicine’s clinical reporting services also highlight genomic alterations that may have prognostic or diagnostic significance, such as NUTM1 fusions in NUT carcinomas, TMPRSS2-ERG in prostate cancers, and BRAF-KIAA1549 in gliomas, as well as context for low/intermediate MSI results in potential cases of Lynch Syndrome with high TMB [115–118].